TipRanks
Axsome Therapeutics Inc (MX:AXSM)
:AXSM
Mexico Market
AXSM
Axsome Therapeutics
RESEARCH TOOLSreports

Axsome Therapeutics (AXSM) Stock Forecast & Price Target

1 Followers
See the Price Targets and Ratings of:

AXSM Analyst Ratings

Strong Buy
13Ratings
Strong Buy
12 Buy
1 Hold
0 Sell
Based on 13 analysts giving stock ratings to
Axsome
Therapeutics
in the past 3 months
TipRanks enables you to focus on the analyst rating consensus of all analysts or only the top performers​ in the past 3 months

AXSM Stock 12 Month Forecast

Average Price Target

$5,010.85
▲(229.88% Upside)
Based on 13 Wall Street analysts offering 12 month price targets for Axsome Therapeutics in the last 3 months. The average price target is $5,010.85 with a high forecast of $6,543.38 and a low forecast of $4,322.07. The average price target represents a 229.88% change from the last price of $1,519.00.
{"navigator":{"disabled":true},"exporting":{"enabled":false},"title":{"text":null},"chart":{"height":200,"style":{"fontFamily":"Roboto Flex, -apple-system, BlinkMacSystemFont, Segoe UI, Roboto, Helvetica, Arial, sans-serif, Apple Color Emoji, Segoe UI Emoji, Segoe UI Symbol","fontWeight":"400","color":"#5d5d5e"},"spacingTop":30,"spacingRight":60,"events":null},"yAxis":{"labels":{"style":{"color":"inherit"},"distance":6,"x":-6,"y":-6,"zIndex":1,"map_label_formatter":{"1518":"$1,518","4031":"$4,031","6544":"$6,544","2774.5":"$2,774.5","5287.5":"$5,287.5"}},"plotLines":[{"color":"rgba(0,0,0,0)","value":6543.375693600001,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":-10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-bottom flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#199ca5\">High </span>\n\n  <span style=\"color:#199ca5\">$7K</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":5010.848228520001,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":0,"text":"<div  class=\"positionrelative hoverZ3 triangleleft flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#828080\">Average </span>\n\n  <span style=\"color:#828080\">$5.01K</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":4322.071839720001,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-top flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#912767\">Low </span>\n\n  <span style=\"color:#912767\">$4.32K</span>\n  </div></div>","useHTML":true}}],"tickPositions":[1518,2774.5,4031,5287.5,6544],"lineColor":"#dddddd","gridLineWidth":1,"gridLineColor":"#dddddd","lineWidth":1,"title":{"text":""}},"plotOptions":{"series":{"states":{"inactive":{"opacity":1}}},"line":{"animation":{"duration":0},"dataLabels":{"allowOverlap":true},"borderWidth":1,"marker":{"enabled":true,"fillColor":"#FFFFFF","radius":3,"lineWidth":2,"symbol":"circle","lineColor":"#828080"}}},"xAxis":{"labels":{"style":{"color":"inherit"},"rotation":0,"map_label_formatter":{"3":"Dec<br/>2025","6":"Mar<br/>2026","9":"Jun<br/>2026","12":"Sep<br/>2026","25":"Sep<br/>2027"}},"tickPositions":[3,6,9,12,25],"plotLines":[{"color":"#dddddd","width":1,"value":12},{"color":"#dddddd","width":1,"value":12}],"lineWidth":0,"gridLineWidth":1,"gridLineColor":"#dddddd","tickLength":0},"legend":{"symbolRadius":0,"symbolPadding":4,"symbolHeight":14,"borderWidth":0,"symbolWidth":14,"align":"left","verticalAlign":"bottom","enabled":false},"tooltip":{"backgroundColor":"rgba(0,0,0,0)","useHTML":true,"borderWidth":0,"borderColor":"rgba(0,0,0,0)","padding":0,"shadow":null,"headerFormat":"","footerFormat":"","pointFormat":"<div class=\"flexccc lineHeight2 bgwhite shadow2 px3 py3 radiismall fonth10_semibold\">\n                <span class=\"colorgray-3 mb4\">{point.date:%b %d ,%Y}</span>\n                <span>Analyst Consensus</span>\n                {point.info}\n          </div>\n           </div>"},"credits":{"enabled":false},"accessibility":{"description":""},"responsive":{"rules":[{"chartOptions":{"chart":{"spacing":[0,0,0,0],"margin":[30,60,40,5]},"xAxis":{"tickPositions":[3,12,25.25]},"yAxis":{"labels":{"enabled":false}},"title":{"text":null},"subtitle":{"text":null}},"condition":{"maxWidth":500}}]},"series":[{"lineWidth":2,"dashStyle":"ShortDash","name":"High","type":"line","color":"#199ca5","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,1519,1905.4904379692307,2291.9808759384614,2678.4713139076925,3064.9617518769232,3451.452189846154,3837.942627815385,4224.433065784616,4610.9235037538465,4997.413941723077,5383.904379692308,5770.394817661539,6156.88525563077,{"y":6543.375693600001,"marker":{"fillColor":"#199ca5","lineColor":"#199ca5","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Average","type":"line","color":"#828080","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,1519,1787.6037098861539,2056.2074197723077,2324.811129658462,2593.4148395446155,2862.01854943077,3130.6222593169236,3399.2259692030775,3667.8296790892314,3936.4333889753852,4205.03709886154,4473.640808747693,4742.244518633847,{"y":5010.848228520001,"marker":{"fillColor":"#828080","lineColor":"#828080","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Low","type":"line","color":"#912767","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,1519,1734.6209107476923,1950.2418214953848,2165.862732243077,2381.4836429907696,2597.1045537384616,2812.725464486154,3028.3463752338466,3243.967285981539,3459.588196729231,3675.2091074769237,3890.830018224616,4106.450928972308,{"y":4322.071839720001,"marker":{"fillColor":"#912767","lineColor":"#912767","enabled":true,"symbol":"circle"}}]},{"type":"line","data":[{"y":1519,"date":1756684800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 43,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":1519,"date":1759276800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 28,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":1519,"date":1761955200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 24,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":1519,"date":1764547200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 27,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":1519,"date":1767225600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 42,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":1519,"date":1769904000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 43,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 2, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":1519,"date":1772323200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 41,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 2, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":1519,"date":1775001600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 34,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":1519,"date":1777593600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 38,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 2, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":1519,"date":1780272000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 39,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 2, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":1519,"date":1782864000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 36,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 2, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":1519,"date":1785542400000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 31,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":1519,"date":1788220800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 32,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"fillColor":"black","lineColor":"black","enabled":true,"symbol":"circle"}},null,null,null,null,null,null,null,null,null,null,null,null],"color":"#0666a7"}]}
Highest Price Target$6,543Average Price Target$5,011Lowest Price Target$4,322
The highest, average, and lowest price target of all analysts. Click on ‘Top Analysts’ to focus on the best performers.

Detailed List of Analyst Forecasts​

Detailed List of Analyst Forecasts​
Analyst Profile
Expert Firm
Price Target
Position
Upside / Downside
Action
Date
Follow
Article
H.C. Wainwright Analyst forecast on MX:AXSM
Ram Selvaraju
H.C. Wainwright
H.C. Wainwright
$4,993.63
Buy
228.74%
Upside
Reiterated
09/21/26
H.C. Wainwright Reaffirms Their Buy Rating on Axsome Therapeutics (AXSM)
RBC Capital Analyst forecast on MX:AXSM
Leonid Timashev
RBC Capital
RBC Capital
$5,114.16
Buy
236.68%
Upside
Reiterated
09/18/26
Analysts Offer Insights on Healthcare Companies: Eli Lilly & Co (NYSE: LLY), BioMarin Pharmaceutical (NASDAQ: BMRN) and Axsome Therapeutics (NASDAQ: AXSM)
Piper Sandler Analyst forecast on MX:AXSM
David Amsellem
Piper Sandler
Piper Sandler
$4,442.61
Buy
192.47%
Upside
Reiterated
09/18/26
Piper Sandler Sticks to Its Buy Rating for Axsome Therapeutics (AXSM)
BMO Capital Analyst forecast on MX:AXSM
Malcolm Hoffman
BMO Capital
BMO Capital
$5,338.02
Buy
251.42%
Upside
Reiterated
09/14/26
Analysts Offer Insights on Healthcare Companies: Scholar Rock Holding (NASDAQ: SRRK), Axsome Therapeutics (NASDAQ: AXSM) and Ionis Pharmaceuticals (NASDAQ: IONS)
Mizuho Securities Analyst forecast on MX:AXSM
Graig Suvannavejh
Mizuho Securities
Mizuho Securities
$5,441.33
Buy
258.22%
Upside
Reiterated
09/11/26
Axsome rises as Mizuho highlights 'big month-over-month jump' for AuvelityAxsome rises as Mizuho highlights 'big month-over-month jump' for Auvelity
Wells Fargo Analyst forecast on MX:AXSM
Benjamin Burnett
Wells Fargo
Wells Fargo
$4,408.17
Buy
190.20%
Upside
Reiterated
09/10/26
Analysts Offer Insights on Healthcare Companies: Zymeworks (NASDAQ: ZYME), Axsome Therapeutics (NASDAQ: AXSM) and Ocugen (NASDAQ: OCGN)
Jefferies Analyst forecast on MX:AXSM
Andrew Tsai
Jefferies
Jefferies
$6,543.38
Buy
330.77%
Upside
Reiterated
08/11/26
Analysts Offer Insights on Healthcare Companies: Cardinal Health (NYSE: CAH), Axsome Therapeutics (NASDAQ: AXSM) and BridgeBio Pharma (NASDAQ: BBIO)
Needham Analyst forecast on MX:AXSM
Ami Fadia
Needham
Needham
$4,597.58→$4,614.8
Buy
203.81%
Upside
Reiterated
08/10/26
Ami Fadia Reiterates Buy on Axsome as Auvelity Outperformance and Alzheimer’s Agitation Launch Momentum Offset Near-Term Margin Pressure
William Blair Analyst forecast on MX:AXSM
Myles Minter
William Blair
William Blair
―
Buy
―
Reiterated
08/10/26
Myles Minter Reiterates Buy on Axsome as Auvelity Outperformance and AXS-12 NDA Acceptance Strengthen Long-Term Growth Outlook
Bank of America Securities Analyst forecast on MX:AXSM
Jason Gerberry
Bank of America Securities
Bank of America Securities
$4,752.56
Buy
212.87%
Upside
Reiterated
08/10/26
Auvelity Momentum and Pipeline Progress Drive Undervalued Upside in Axsome, Supporting Buy Rating
Guggenheim Analyst forecast on MX:AXSM
Yatin Suneja
Guggenheim
Guggenheim
$4,477.05→$4,735.34
Buy
211.74%
Upside
Reiterated
08/10/26
Axsome Therapeutics price target raised to $275 from $260 at GuggenheimAxsome Therapeutics price target raised to $275 from $260 at Guggenheim
TD Cowen Analyst forecast on MX:AXSM
Joseph Thome
TD Cowen
TD Cowen
$5,165.82→$5,424.11
Buy
257.08%
Upside
Reiterated
08/10/26
Analysts Offer Insights on Healthcare Companies: Heron Therapeutics (NASDAQ: HRTX), Aquestive Therapeutics (NASDAQ: AQST) and Axsome Therapeutics (NASDAQ: AXSM)
Morgan Stanley Analyst forecast on MX:AXSM
Sean Laaman
Morgan Stanley
Morgan Stanley
$4,167.1→$4,322.07
Hold
184.53%
Upside
Reiterated
08/10/26
Axsome Therapeutics (AXSM) Receives a Hold from Morgan Stanley
Deutsche Bank Analyst forecast on MX:AXSM
David Hoang
Deutsche Bank
Deutsche Bank
$4,838.65→$4,821.43
Buy
217.41%
Upside
Assigned
05/05/26
Axsome Therapeutics price target raised to $281 from $245 at Deutsche BankAxsome Therapeutics price target raised to $281 from $245 at Deutsche Bank
Robert W. Baird Analyst forecast on MX:AXSM
Brian Skorney
Robert W. Baird
Robert W. Baird
$4,149.88→$4,235.97
Buy
178.87%
Upside
Reiterated
05/05/26
Axsome Therapeutics price target raised to $246 from $241 at BairdAxsome Therapeutics price target raised to $246 from $241 at Baird
Analyst Type
Any
Any
Human Analysts
Ranks
Any
Any
Analyst Rating
Any
Any
Upside/ Downside
Any
Any
Action
Any
Any
Analyst Profile
Expert Firm
Price Target
Position
Upside / Downside
Action
Date
Follow
Article
H.C. Wainwright Analyst forecast on MX:AXSM
Ram Selvaraju
H.C. Wainwright
H.C. Wainwright
$4,993.63
Buy
228.74%
Upside
Reiterated
09/21/26
H.C. Wainwright Reaffirms Their Buy Rating on Axsome Therapeutics (AXSM)
RBC Capital Analyst forecast on MX:AXSM
Leonid Timashev
RBC Capital
RBC Capital
$5,114.16
Buy
236.68%
Upside
Reiterated
09/18/26
Analysts Offer Insights on Healthcare Companies: Eli Lilly & Co (NYSE: LLY), BioMarin Pharmaceutical (NASDAQ: BMRN) and Axsome Therapeutics (NASDAQ: AXSM)
Piper Sandler Analyst forecast on MX:AXSM
David Amsellem
Piper Sandler
Piper Sandler
$4,442.61
Buy
192.47%
Upside
Reiterated
09/18/26
Piper Sandler Sticks to Its Buy Rating for Axsome Therapeutics (AXSM)
BMO Capital Analyst forecast on MX:AXSM
Malcolm Hoffman
BMO Capital
BMO Capital
$5,338.02
Buy
251.42%
Upside
Reiterated
09/14/26
Analysts Offer Insights on Healthcare Companies: Scholar Rock Holding (NASDAQ: SRRK), Axsome Therapeutics (NASDAQ: AXSM) and Ionis Pharmaceuticals (NASDAQ: IONS)
Mizuho Securities Analyst forecast on MX:AXSM
Graig Suvannavejh
Mizuho Securities
Mizuho Securities
$5,441.33
Buy
258.22%
Upside
Reiterated
09/11/26
Axsome rises as Mizuho highlights 'big month-over-month jump' for AuvelityAxsome rises as Mizuho highlights 'big month-over-month jump' for Auvelity
Wells Fargo Analyst forecast on MX:AXSM
Benjamin Burnett
Wells Fargo
Wells Fargo
$4,408.17
Buy
190.20%
Upside
Reiterated
09/10/26
Analysts Offer Insights on Healthcare Companies: Zymeworks (NASDAQ: ZYME), Axsome Therapeutics (NASDAQ: AXSM) and Ocugen (NASDAQ: OCGN)
Jefferies Analyst forecast on MX:AXSM
Andrew Tsai
Jefferies
Jefferies
$6,543.38
Buy
330.77%
Upside
Reiterated
08/11/26
Analysts Offer Insights on Healthcare Companies: Cardinal Health (NYSE: CAH), Axsome Therapeutics (NASDAQ: AXSM) and BridgeBio Pharma (NASDAQ: BBIO)
Needham Analyst forecast on MX:AXSM
Ami Fadia
Needham
Needham
$4,597.58→$4,614.8
Buy
203.81%
Upside
Reiterated
08/10/26
Ami Fadia Reiterates Buy on Axsome as Auvelity Outperformance and Alzheimer’s Agitation Launch Momentum Offset Near-Term Margin Pressure
William Blair Analyst forecast on MX:AXSM
Myles Minter
William Blair
William Blair
―
Buy
―
Reiterated
08/10/26
Myles Minter Reiterates Buy on Axsome as Auvelity Outperformance and AXS-12 NDA Acceptance Strengthen Long-Term Growth Outlook
Bank of America Securities Analyst forecast on MX:AXSM
Jason Gerberry
Bank of America Securities
Bank of America Securities
$4,752.56
Buy
212.87%
Upside
Reiterated
08/10/26
Auvelity Momentum and Pipeline Progress Drive Undervalued Upside in Axsome, Supporting Buy Rating
Guggenheim Analyst forecast on MX:AXSM
Yatin Suneja
Guggenheim
Guggenheim
$4,477.05→$4,735.34
Buy
211.74%
Upside
Reiterated
08/10/26
Axsome Therapeutics price target raised to $275 from $260 at GuggenheimAxsome Therapeutics price target raised to $275 from $260 at Guggenheim
TD Cowen Analyst forecast on MX:AXSM
Joseph Thome
TD Cowen
TD Cowen
$5,165.82→$5,424.11
Buy
257.08%
Upside
Reiterated
08/10/26
Analysts Offer Insights on Healthcare Companies: Heron Therapeutics (NASDAQ: HRTX), Aquestive Therapeutics (NASDAQ: AQST) and Axsome Therapeutics (NASDAQ: AXSM)
Morgan Stanley Analyst forecast on MX:AXSM
Sean Laaman
Morgan Stanley
Morgan Stanley
$4,167.1→$4,322.07
Hold
184.53%
Upside
Reiterated
08/10/26
Axsome Therapeutics (AXSM) Receives a Hold from Morgan Stanley
Deutsche Bank Analyst forecast on MX:AXSM
David Hoang
Deutsche Bank
Deutsche Bank
$4,838.65→$4,821.43
Buy
217.41%
Upside
Assigned
05/05/26
Axsome Therapeutics price target raised to $281 from $245 at Deutsche BankAxsome Therapeutics price target raised to $281 from $245 at Deutsche Bank
Robert W. Baird Analyst forecast on MX:AXSM
Brian Skorney
Robert W. Baird
Robert W. Baird
$4,149.88→$4,235.97
Buy
178.87%
Upside
Reiterated
05/05/26
Axsome Therapeutics price target raised to $246 from $241 at BairdAxsome Therapeutics price target raised to $246 from $241 at Baird
Stocks with the Highest Top Analyst Consensus in the Healthcare Sector
ARWRArrowhead Pharmaceuticals
PTGXProtagonist Therapeutics
ESTAEstablishment Labs Holdings
ZVRAZevra Therapeutics
IMUXImmunic
Find stocks in the Healthcare sector that are highly recommended by Top Performing Analysts.

Best Analysts Covering Axsome Therapeutics

3 Months
Joon LeeTruist Financial
Success Rate
19/27 ratings generated profit
70%
Average Return
+15.15%
Copying Joon Lee's trades and holding each position for 3 Months would result in 70.37% of your transactions generating a profit, with an average return of +15.15% per trade.
1 Year
Marc GoodmanLeerink Partners
Success Rate
31/32 ratings generated profit
97%
Average Return
+62.26%
Copying Marc Goodman's trades and holding each position for 1 Year would result in 96.88% of your transactions generating a profit, with an average return of +62.26% per trade.
2 Years
Marc GoodmanLeerink Partners
Success Rate
32/32 ratings generated profit
100%
Average Return
+108.53%
Copying Marc Goodman's trades and holding each position for 2 Years would result in 100.00% of your transactions generating a profit, with an average return of +108.53% per trade.
The Best Analyst Covering tool allows you to follow the analysts who have the best success rates and average returns on a specific stock. Only analysts that gave a Buy or Sell rating on the stock in the past 12 months are eligible for inclusion in this tool. Follow the analysts of your choice to receive real-time updates when they publish a new rating.

AXSM Analyst Recommendation Trends

Rating
May 26
Jun 26
Jul 26
Aug 26
Sep 26
Strong Buy
2
1
1
2
2
Buy
36
38
35
29
30
Hold
2
2
2
1
1
Sell
0
0
0
0
0
Strong Sell
0
0
0
0
0
total
40
41
38
32
33
In the current month, AXSM has received 32 Buy Ratings, 1 Hold Ratings, and 0 Sell Ratings. AXSM average Analyst price target in the past 3 months is 5,010.85.
Each month's total comprises the sum of three months' worth of ratings.

AXSM Financial Forecast

AXSM Earnings Forecast

Next quarter’s earnings estimate for AXSM is -$8.30 with a range of -$16.98 to -$0.51. The previous quarter’s EPS was -$16.81. AXSM beat its EPS estimate ― of the time in the past 12 months, while its overall industry beat the EPS estimate 57.80% of the time in the same period. In the last calendar year AXSM has Performed in-line its overall industry.
Next quarter’s earnings estimate for AXSM is -$8.30 with a range of -$16.98 to -$0.51. The previous quarter’s EPS was -$16.81. AXSM beat its EPS estimate ― of the time in the past 12 months, while its overall industry beat the EPS estimate 57.80% of the time in the same period. In the last calendar year AXSM has Performed in-line its overall industry.

AXSM Sales Forecast

Next quarter’s sales forecast for AXSM is $4.39B with a range of $3.87B to $4.79B. The previous quarter’s sales results were $3.71B. AXSM beat its sales estimates ― of the time in past 12 months, while its overall industry beat sales estimates 50.04% of the time in the same period. In the last calendar year AXSM has Performed in-line its overall industry.
Next quarter’s sales forecast for AXSM is $4.39B with a range of $3.87B to $4.79B. The previous quarter’s sales results were $3.71B. AXSM beat its sales estimates ― of the time in past 12 months, while its overall industry beat sales estimates 50.04% of the time in the same period. In the last calendar year AXSM has Performed in-line its overall industry.

AXSM Stock Forecast FAQ

What is MX:AXSM’s average 12-month price target, according to analysts?
Based on analyst ratings, Axsome Therapeutics Inc’s 12-month average price target is 5,010.85.
    What is MX:AXSM’s upside potential, based on the analysts’ average price target?
    Axsome Therapeutics Inc has 229.88% upside potential, based on the analysts’ average price target.
      Can I see which stocks the top-ranking analysts are rating?
      Yes, go to the Analysts’ Top Stocks tool to see stocks with a Strong Buy or Strong Sell analyst rating consensus, according to the top performers.
        How can I follow the stock ratings of top Wall Street analysts?
        Head over to our Expert Center to see a list of the top 100 Wall Street analysts and follow the analysts of your choice. Visit their profiles for more details about their stock ratings and see how they perform on a stock-by-stock basis.
          Is Axsome Therapeutics Inc a Buy, Sell or Hold?
          Axsome Therapeutics Inc has a consensus rating of Strong Buy, which is based on 12 buy ratings, 1 hold ratings and 0 sell ratings.
            What is Axsome Therapeutics Inc’s share price target?
            The average share price target for Axsome Therapeutics Inc is 5,010.85. This is based on 13 Wall Streets Analysts 12-month price targets, issued in the past 3 months.
            The highest analyst share price target is $6,543.38 ,and the lowest forecast is $4,322.07. The average share price target represents 229.88% Increase from the current price of $1,519.
              What do analysts say about Axsome Therapeutics Inc?
              Axsome Therapeutics Inc’s analyst rating consensus is a Strong Buy. This is based on the ratings of 13 Wall Streets Analysts.
                How can I buy shares of Axsome Therapeutics Inc?
                To buy shares of MX:AXSM, you can open a brokerage account. See exclusive account opening deals on our Best Online Brokers page.